File this under “What were they thinking?”
For the second time this year, Pfizer (PFE) has made substantial price hikes on some of its medicines, a move that disregards blistering criticism of the pharmaceutical industry over the cost of prescription drugs.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author
geee,,,maybe its because all MEDICINE manufacturers are being sued by Adults who’s 30 year old ,”babies,”choose to use medicines like idiots,,,,,,maryw
If one wants to ‘observe’ that ‘Big Pharma’ is … uh, ‘s______g’ the customers, then using price increases on ‘the little blue pill’ is a fine point of emphasis.
New normal when one cannot create and develop new drugs for masses or expensive drugs for limited patients. Revenue has to go up to look good.
Shall we call this a ‘side effect’ of the Viagra patent extension to March 2020?